Luis Andrés López-FernÃ;ndez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9079174/publications.pdf

Version: 2024-02-01

82 papers

2,173 citations

236612 25 h-index 264894 42 g-index

89 all docs 89 docs citations

89 times ranked 3126 citing authors

#	Article	IF	Citations
1	Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines. Clinical and Translational Oncology, 2022, 24, 483-494.	1.2	19
2	Pharmacogenetics to Avoid Adverse Drug Reactions. Journal of Personalized Medicine, 2022, 12, 159.	1.1	O
3	ABO blood group is involved in the quality of the specific immune response anti-SARS-CoV-2. Virulence, 2022, 13, 30-45.	1.8	13
4	Pharmacogenetics of trough serum antiâ€₹NF levels in paediatric inflammatory bowel disease. British Journal of Clinical Pharmacology, 2021, 87, 447-457.	1.1	12
5	Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabineâ€Induced Handâ€Foot Syndrome. Clinical Pharmacology and Therapeutics, 2021, 109, 462-470.	2.3	6
6	Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease. Pharmaceutics, 2021, 13, 77.	2.0	14
7	Comparison of a new rapid method for determination of serum anti-adalimumab and anti-infliximab antibodies with two established ELISA kits. Journal of Pharmaceutical and Biomedical Analysis, 2021, 198, 114003.	1.4	9
8	DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach. Journal of Personalized Medicine, 2021, 11, 792.	1.1	2
9	Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days. Frontiers in Immunology, 2021, 12, 726960.	2.2	16
10	Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease. Pharmaceutics, 2021, 13, 1786.	2.0	5
11	Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study. Pharmaceutics, 2021, 13, 2036.	2.0	8
12	Comprehensive Flow Cytometry Profiling of the Immune System in COVID-19 Convalescent Individuals. Frontiers in Immunology, 2021, 12, 793142.	2.2	13
13	Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis. Pharmacological Research, 2020, 152, 104594.	3.1	17
14	Genetic Predictors of Longâ€ŧerm Response to Antitumor Necrosis Factor Agents in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2020, 71, 508-515.	0.9	12
15	Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease. International Journal of Molecular Sciences, 2020, 21, 3364.	1.8	22
16	New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine. Cancer Chemotherapy and Pharmacology, 2020, 86, 45-54.	1.1	13
17	Transcriptional signature of resting-memory CD4 T cells differentiates spontaneous from treatment-induced HIV control. Journal of Molecular Medicine, 2020, 98, 1093-1105.	1.7	3
18	Differential Expression of SMAD Genes and S1PR1 on Circulating CD4+ T Cells in Multiple Sclerosis and Crohn's Disease. International Journal of Molecular Sciences, 2020, 21, 676.	1.8	15

#	Article	IF	Citations
19	Genetic predictors of long-term response and trough levels of infliximab in crohn's disease. Pharmacological Research, 2019, 149, 104478.	3.1	17
20	Comments on: "Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan― Pharmacological Research, 2019, 145, 104288.	3.1	0
21	Expression of Concern: Gene trap analysis of germ cell signaling to Sertoli cells: NGF-TrkA mediated induction of Fra1 and Fos by post-meiotic germ cells. Journal of Cell Science, 2019, 132, .	1.2	2
22	Comparison of a new rapid method for the determination of adalimumab serum levels with two established ELISA kits. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1906-1914.	1.4	18
23	Genes differentially expressed by methylprednisolone in vivo in CD4 T lymphocytes from multiple sclerosis patients: potential biomarkers. Pharmacogenomics Journal, 2018, 18, 98-105.	0.9	12
24	ATP-Binding Cassette Transporters in the Clinical Implementation of Pharmacogenetics. Journal of Personalized Medicine, 2018, 8, 40.	1.1	9
25	Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene. Cancer Management and Research, 2018, Volume 10, 4517-4522.	0.9	4
26	Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan. Pharmacological Research, 2018, 136, 133-139.	3.1	22
27	Identification of new SNPs associated with severe toxicity to capecitabine. Pharmacological Research, 2017, 120, 133-137.	3.1	39
28	Using pharmacogenetics to prevent severe adverse reactions to capecitabine. Pharmacogenomics, 2017, 18, 1199-1213.	0.6	2
29	Use of exome sequencing to determine the full profile of genetic variants in the fluoropyrimidine pathway in colorectal cancer patients affected by severe toxicity. Pharmacogenomics, 2017, 18, 1215-1223.	0.6	12
30	Cost–effectiveness of screening for <i>DPYD</i> polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines. Pharmacogenomics, 2016, 17, 979-984.	0.6	32
31	Clinical implementation of pharmacogenetics. Drug Metabolism and Personalized Therapy, 2016, 31, 9-16.	0.3	21
32	Ammonia Affects Astroglial Proliferation in Culture. PLoS ONE, 2015, 10, e0139619.	1.1	19
33	Variants in <i>CDA</i> and <i>ABCB1</i> ere predictors of capecitabine-related adverse reactions in colorectal cancer. Oncotarget, 2015, 6, 6422-6430.	0.8	49
34	Identification of genetic variants associated with capecitabine-induced hand–foot syndrome through integration of patient and cell line genomic analyses. Pharmacogenetics and Genomics, 2014, 24, 231-237.	0.7	10
35	A genome-wide association study on copy-number variation identifies a 11q11 loss as a candidate susceptibility variant for colorectal cancer. Human Genetics, 2014, 133, 525-534.	1.8	20
36	Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer. Cancer Chemotherapy and Pharmacology, 2013, 71, 1463-1472.	1.1	39

#	Article	IF	CITATIONS
37	Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration. Pharmacogenomics Journal, 2013, 13, 209-217.	0.9	37
38	BMP2 / BMP4 colorectal cancer susceptibility loci in northern and southern European populations. Carcinogenesis, 2013, 34, 314-318.	1.3	14
39	Estradiol downregulates NF-κb translocation by Ikbkg transcriptional repression in dendritic cells. Genes and Immunity, 2013, 14, 462-469.	2.2	15
40	A colorectal cancer genome-wide association study in a Spanish cohort identifies two variants associated with colorectal cancer risk at 1p33 and 8p12. BMC Genomics, 2013, 14, 55.	1.2	36
41	Interferon-stimulated genes are associated with peginterferon/ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients. Aids, 2013, 27, 687-696.	1.0	10
42	Endocrine disruptors, gene deregulation and male germ cell tumors. International Journal of Developmental Biology, 2013, 57, 225-239.	0.3	38
43	Pharmacogenetic biomarkers for predisposition to toxicity to adjuvant FOLFOX/XELOX in colorectal cancer Journal of Clinical Oncology, 2013, 31, 390-390.	0.8	1
44	Ammonia induces aquaporin-4 rearrangement in the plasma membrane of cultured astrocytes. Neurochemistry International, 2012, 61, 1314-1324.	1.9	20
45	Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients. Pharmacogenomics, 2012, 13, 1173-1191.	0.6	23
46	Carbosilane Dendrimer 2G-NN16 Represses Tc17 Differentiation in Primary T CD8+ Lymphocytes. Molecular Pharmaceutics, 2012, 9, 102-110.	2.3	12
47	The inhibition of Th17 immune response inÂvitro and inÂvivo by the carbosilane dendrimer 2G-NN16. Biomaterials, 2012, 33, 4002-4009.	5.7	17
48	The effects of different endocrine disruptors defining compound-specific alterations of gene expression profiles in the developing testis. Reproductive Toxicology, 2012, 33, 106-115.	1.3	39
49	Carbosilane dendrimer nanotechnology outlines of the broad HIV blocker profile. Journal of Controlled Release, 2012, 161, 949-958.	4.8	82
50	1338 WHOLE GENOME EXPRESSION PROFILE DEFINES DIFFERENTIALLY EXPRESSED GENES IN HIV/HCV-COINFECTED PATIENTS ACCORDING TO PEGIFNA/RBV TREATMENT OUTCOME AND TO IL28B GENOTYPE. Journal of Hepatology, 2011, 54, S528.	1.8	0
51	Gene Therapy in HIVâ€Infected Cells to Decrease Viral Impact by Using an Alternative Delivery Method. ChemMedChem, 2010, 5, 921-929.	1.6	48
52	Selective Induction of Host Genes by MVA-B, a Candidate Vaccine against HIV/AIDS. Journal of Virology, 2010, 84, 8141-8152.	1.5	31
53	Carbosilane Dendrimers to Transfect Human Astrocytes with Small Interfering RNA Targeting Human Immunodeficiency Virus. BioDrugs, 2010, 24, 331-343.	2.2	66
54	Gene-expression profiling in pancreatic cancer. Expert Review of Molecular Diagnostics, 2010, 10, 591-601.	1.5	30

#	Article	IF	Citations
55	<i>ABCB1</i> gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients. Pharmacogenomics, 2010, 11, 1715-1723.	0.6	36
56	Changes in Gene Expression Pattern of Human Primary Macrophages Induced by Carbosilane Dendrimer 2G-NN16. Pharmaceutical Research, 2009, 26, 577-586.	1.7	37
57	Astrocytes express Mxi2, a splice isoform of p38MAPK. Journal of Molecular Histology, 2009, 40, 325-329.	1.0	O
58	Molecular Characterization of Spontaneous Mesenchymal Stem Cell Transformation. PLoS ONE, 2008, 3, e1398.	1.1	147
59	Distinct Gene Expression Profiling after Infection of Immature Human Monocyte-Derived Dendritic Cells by the Attenuated Poxvirus Vectors MVA and NYVAC. Journal of Virology, 2007, 81, 8707-8721.	1.5	88
60	Genomic Profiling of Circulating Plasma RNA for the Analysis of Cancer. Clinical Chemistry, 2007, 53, 1860-1863.	1.5	32
61	Activation of the epidermal growth factor signalling pathway by tissue plasminogen activator in pancreas cancer cells. Gut, 2007, 56, 1266-1274.	6.1	24
62	Effect of ammonia on ciliary neurotrophic factor mRNA and protein expression and its upstream signalling pathway in cultured rat astroglial cells: possible implication of c-fos, Sp1 and p38MAPK. Neuropathology and Applied Neurobiology, 2007, 33, 420-430.	1.8	7
63	Cascade of transcriptional induction and repression during IL-2 deprivation-induced apoptosis. Immunology Letters, 2007, 112, 9-29.	1.1	10
64	Possible implication of ciliary neurotrophic factor (CNTF) and \hat{l}^2 -synuclein in the ammonia effect on cultured rat astroglial cells: A study using DNA and protein microarrays. Neurochemistry International, 2006, 48, 729-738.	1.9	15
65	Host Response to the Attenuated Poxvirus Vector NYVAC: Upregulation of Apoptotic Genes and NF-ÎB-Responsive Genes in Infected HeLa Cells. Journal of Virology, 2006, 80, 985-998.	1.5	33
66	Human Gene Profiling in Response to the Active Protein Kinase, Interferon-induced Serine/threonine Protein Kinase (PKR), in Infected Cells. Journal of Biological Chemistry, 2006, 281, 18734-18745.	1.6	30
67	Microarray Analysis Reveals Characteristic Changes of Host Cell Gene Expression in Response to Attenuated Modified Vaccinia Virus Ankara Infection of Human HeLa Cells. Journal of Virology, 2004, 78, 5820-5834.	1.5	77
68	Differential expression of Ran GTPase during HMBA-induced differentiation in murine erythroleukemia cells. Leukemia Research, 2003, 27, 607-615.	0.4	15
69	Cellular Gene Expression Survey of Vaccinia Virus Infection of Human HeLa Cells. Journal of Virology, 2003, 77, 6493-6506.	1.5	107
70	A Novel Germ Line-specific Gene of the Phosducin-like Protein (PhLP) Family. Journal of Biological Chemistry, 2003, 278, 1751-1757.	1.6	20
71	Gene Control in Germinal Differentiation: Rnf6, a Transcription Regulatory Protein in the Mouse Sertoli Cell. Molecular and Cellular Biology, 2002, 22, 3488-3496.	1.1	17
72	Ilf2 is regulated during meiosis and associated to transcriptionally active chromatin. Mechanisms of Development, 2002, 111, 153-157.	1.7	21

#	Article	IF	CITATIONS
73	Ran GTPase expression during early development of the mouse embryo. Mechanisms of Development, 2002, 113, 103-106.	1.7	8
74	DNA polymerase lambda (Pol \hat{l} »), a novel eukaryotic DNA polymerase with a potential role in meiosis 1 1Edited by M. Yaniv. Journal of Molecular Biology, 2000, 301, 851-867.	2.0	268
75	Fhx (Foxj2) expression is activated during spermatogenesis and very early in embryonic development. Mechanisms of Development, 2000, 97, 157-160.	1.7	34
76	Tex27, a Gene Containing a Zinc-Finger Domain, Is Up-Regulated during the Haploid Stages of Spermatogenesis. Experimental Cell Research, 1999, 249, 320-326.	1.2	23
77	Tex261,a Novel Gene Presumably Related but Distinct from Steroidogenic Acute Regulatory (StAR) Gene, Is Regulated during the Development of Germ Cells. Biochemical and Biophysical Research Communications, 1998, 242, 565-569.	1.0	12
78	Analysis of Gene Regulation in Sertoli Cells by a Gene Trap Approach. Advances in Experimental Medicine and Biology, 1998, 444, 153-162.	0.8	0
79	H3.3A Variant Histone mRNA Containing an α-Globin Insertion: Modulated Expression During Mouse Gametogenesis Correlates with Meiotic Onset. DNA and Cell Biology, 1997, 16, 639-644.	0.9	3
80	The cytosolic aldehyde dehydrogenase gene (Aldh1) is developmentally expressed in Leydig cells. FEBS Letters, 1997, 407, 225-229.	1.3	27
81	Characterization of genes expressed early in mouse spermatogenesis, isolated from a subtractive cDNA library. Mammalian Genome, 1996, 7, 698-700.	1.0	19
82	Different developmental pattern of N-ras and unr gene expression in mouse gametogenic and somatic tissues. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1995, 1263, 10-16.	2.4	12